TCA Cellular Therapy, Covington, LA 70433, USA.
Br Med Bull. 2011;98:187-97. doi: 10.1093/bmb/ldr017. Epub 2011 May 17.
Peripheral vascular disease is the leading cause of limb ischemia (LI). LI is manifested by claudication, ischemic rest pain, ulcers or gangrene. It is the result of peripheral arterial disease due to atherosclerosis. Over the last decade, several centers around the world have initiated clinical trials utilizing stem cells as a treatment for this disease.
Published medical literature, clinical trials announced in clinical trials.gov and TCA cellular therapy experience.
There is general agreement that stem cells are useful for LI.
These arise from the type of cells, dose, route of administration and methods to evaluate efficacy.
Growing evidence suggests that bone marrow derived-mesenchymal stem cells are as good as or superior to mononuclear cells, and a combination of both cell types may be even better.
Based on current trials and publications, several promising biological products could become part of the therapeutic arsenal for LI. This may include combinations of more than one type of adult/induced pluripotent stem cells/embryonic stem cells, use of stem cells with growth factors or extracellular matrix molecules.
周围血管疾病是导致肢体缺血（LI）的主要原因。LI 的表现为跛行、缺血性静息痛、溃疡或坏疽。它是由于动脉粥样硬化导致的外周动脉疾病引起的。在过去的十年中，世界上有几个中心已经启动了利用干细胞作为这种疾病治疗方法的临床试验。
已发表的医学文献、在 clinicaltrials.gov 上公布的临床试验和 TCA 细胞治疗经验。
普遍认为干细胞对 LI 有用。
这些争议源于细胞类型、剂量、给药途径和评估疗效的方法。
越来越多的证据表明，骨髓来源的间充质干细胞与单核细胞一样有效，甚至两者的组合可能更好。
基于目前的试验和出版物，几种有前途的生物产品可能成为 LI 治疗武器库的一部分。这可能包括多种类型的成人/诱导多能干细胞/胚胎干细胞的组合，使用带有生长因子或细胞外基质分子的干细胞。
